TITLE:
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

CONDITION:
HIV Infections

INTERVENTION:
Atevirdine mesylate

SUMMARY:

      To determine the tolerance and antiviral response of two different doses of atevirdine
      mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350
      cells/mm3, who also take zidovudine (AZT).
    

DETAILED DESCRIPTION:

      Patients are randomized to 1 of 3 treatment groups: U-87201E at 1 of 2 doses or placebo
      administered every 8 hours. Patients must have taken AZT for at least 3 months prior to
      randomization.
    

ELIGIBILITY:
Gender: All
Age: 13 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Primary or secondary prophylaxis for opportunistic infections.

        Patients must have:

          -  HIV infection.

          -  Symptoms (currently or prior to enrollment) included in Category B or C of CDC
             classification, although THE FOLLOWING CURRENT ACUTE MEDICAL CONDITIONS ARE NOT
             ALLOWED:

          -  Cryptococcosis

          -  Pneumocystis carinii pneumonia

          -  Herpes zoster

          -  Histoplasmosis

          -  CMV

          -  Hepatic or renal disease

          -  Lymphoma.

          -  CD4 count 50 - 350 cells/mm3 within 14 days prior to study entry.

          -  Ongoing therapy with AZT at 500 - 600 mg total daily dose for at least 3 months prior
             to study entry.

          -  Consent of parent, guardian, or person with power of attorney if less than 18 years
             of age.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions are excluded:

          -  Intolerance to AZT.

          -  Current diagnosis of malignancy for which systemic therapy will be required during
             the study.

        Concurrent Medication:

        Excluded:

          -  Any other investigational drugs.

        Prior Medication:

        Excluded:

          -  Cytotoxic chemotherapy within 1 month prior to study entry.

          -  Prior U-87201E or any other non-nucleoside antiretroviral medications, including but
             not limited to nevirapine, TIBO R-82150 or TIBO R-82913, L-697639 or L-696229,
             U-90152S, or any protease inhibitors.

          -  Antiretroviral agents other than AZT within 3 months prior to study entry.

        Required:

          -  AZT for at least 3 months prior to study entry. Present use of excessive alcohol or
             illicit drugs.
      
